Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Deals Digital

Ping An Healthcare and Technology Partners with Chugai Pharmaceutical to Establish Angina Pectoris Center

Fineline Cube Apr 26, 2023

Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also recognized as PingAn Good Doctor,...

Company Drug

Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial

Fineline Cube Apr 26, 2023

Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing...

Company Deals

Tot Biopharmaceutical and Shanghai Escugen Partner on ADC Development and Commercialization

Fineline Cube Apr 26, 2023

China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai...

Company Drug

Zhaoke Ophthalmology’s US Partner Visus Therapeutics Reports Positive Phase III Results

Fineline Cube Apr 26, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its...

Company Deals

Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech

Fineline Cube Apr 26, 2023

Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions...

Company Deals

Sable Therapeutics and Liuqiang Medical Ink Licensing Deal for Aesthetic Fat Reduction Patch

Fineline Cube Apr 26, 2023

US-based Sable Therapeutics has announced plans to sign a licensing agreement with China-based Liuqiang Medical...

Company

Olympus Corp. to Invest $40.6 Million in New Endoscope Factory in Suzhou, China

Fineline Cube Apr 25, 2023

Japan-based optics giant Olympus Corp. is expanding its footprint in China with a planned investment...

Company Deals

Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software

Fineline Cube Apr 25, 2023

Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of...

Company Deals

Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions

Fineline Cube Apr 25, 2023

Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk...

Company Deals

Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics

Fineline Cube Apr 25, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is...

Company Drug

Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia

Fineline Cube Apr 25, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has...

Company Medical Device

Rainmed Medical’s caIMR System Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Apr 25, 2023

China-based Rainmed Medical Limited has announced that it has received market approval from the National...

Company

WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1

Fineline Cube Apr 25, 2023

WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the...

Company Legal / IP

SMPA Suspends Procurement of Levornidazole by Warrant Pharmaceutical Over IP Concerns

Fineline Cube Apr 25, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification to suspend the procurement status...

Company Deals

Tot Biopharmaceutical Partners with Suzhou Smart Nuclide on Radioactive Drug Development

Fineline Cube Apr 25, 2023

China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou...

Company Drug

GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14

Fineline Cube Apr 24, 2023

The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of...

Company Drug

Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan

Fineline Cube Apr 24, 2023

China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for...

Company Deals

Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million

Fineline Cube Apr 24, 2023

Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire...

Company Drug

Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor

Fineline Cube Apr 24, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies

Fineline Cube Apr 24, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval...

Posts pagination

1 … 524 525 526 … 658

Recent updates

  • Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.